



FOR IMMEDIATE RELEASE

ETUBICS PRESENTS AT NATIONAL CANCER INSTITUTE'S SBIR INVESTOR FORUM

SEATTLE (XXXX) – Etubics Corporation, a clinical-stage biotechnology company with a proprietary Adenovirus Vector Vaccines Platform (AVVP) technology that enables the rapid generation of therapeutic and preventative vaccines, has been invited to present at the National Cancer Institute's SBIR Investor Forum at Stanford University from 10:15 a.m. to 10:30 a.m. on Tuesday, November 9, 2010. Etubics' patented AVVP has been reported to allow for induction of robust immune responses to multiple disease transgene antigens.

The 2010 SBIR Investor Forum aims to connect the strongest and most promising National Cancer Institute (NCI) SBIR funded companies with life science investors and strategic partners. The conference provides the opportunity for attendees to get a first look at some of the best emerging companies focused on innovative cancer-related technologies, and to establish new collaborations that will expedite the commercialization of these products. Etubics was one of 14 companies chosen to present at this event.

Etubics will present on its therapeutic colon cancer vaccine program, which has been funded by the NCI and is currently in Phase I/II Clinical Trials at Duke University. Etubics therapeutic colon cancer vaccine utilizes the Company's novel AVVP technology to target carcinoembryonic antigen (CEA) expressing cancers. CEA is over-expressed in colorectal cancers, as well as a small percentage of lung, breast and pancreas cancers. Etubics therapeutic colon cancer vaccine is designed to show a cell mediated immune response in patients which could result in reduction of tumor size and increased levels of anti-cancer immunity as seen in preclinical models.

About Etubics

Etubics Corporation is a Seattle based biopharmaceutical company with technology that enables the rapid, cost-effective development and commercialization of therapeutic and preventative vaccines targeting hard to treat diseases. Etubics is currently in clinical trials with a colon cancer therapeutic vaccine. Led by an experienced scientific and management team, Etubics' patented platform leverages the advantages of vector technology, while overcoming historical safety and re-immunization issues of earlier platforms. Etubics was established by Dr. Frank R. Jones and is currently engaged in research and development of its proprietary and novel adenovirus vector vaccine candidates. www.etubics.com.

Statements herein relating to future financial, business performance, conditions or strategies and other financial and business matters, including expectations regarding future revenues and operating expenses, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act. Etubics is a private company. Etubics cautions that these forward-looking statements are subject to numerous assumptions, risks and uncertainties which change over time. Factors that may cause actual results to differ materially from the results discussed in the forward-looking statements or historical experience include risks and uncertainties, including the failure by Etubics to secure and maintain relationships with collaborators; risks relating to the early state of Etubics' product candidates under development; uncertainties relating to clinical trials; risks relating to the commercialization, if any, of Etubics proposed candidates; dependence on the efforts of third parties; dependence on intellectual property; and risks that it may lack the financial resources and access to capital to fund its operations. Further information on the factors and risks that could affect Etubics business, financial conditions and results of operations, are contained in Etubics' documents on file at the Company. These forward-looking statements speak only as of the date of this press release and Etubics assumes no duty to update forward-looking statements.

###

Investor/Media contact:

Kimberly Jones
Phone: (206) 838-5110 Ext. 110
kimberly@etubics.com